Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab as a radiotherapy alternative in pediatric classical Hodgkin lymphoma
ChiCTR2000033599Phase 4Recruiting
- Sponsor
- Beijing Boren Hospital
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tislelizumab in classical Hodgkin lymphoma (cHL), sponsored by Beijing Boren Hospital. Primary endpoints: Pharmacokinetics, Safety and 1 more. Started Jun 2020; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on ChiCTR2000033599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033599.